Inhibitors of Transporters or Uptake of Monoaminergic Neurotransmitters

Summary

 

Technology Description

 

This technology is a simple and efficient way for synthesizing Synosutine, a drug to be potentially used to treat depression and neuropathic pain.

 

Features & Benefits

 

  • Much more efficient and quicker synthesis pathway than that for Cymbalta
  • More balanced inhibition of serotonin and norepinephrine transporters makes Synosutine potentially a better treatment for neuropathic pain
  • In vitro binding and in vivo microdialysis data available

 

Applications

 

  • Treatment for depression and neuropathic pain

 

Background of Invention

 

One form of medical treatment for depression and neuropathic pain features a dual inhibitor called Cymbalta. This drug is manufactured and marketed by Eli Lilly. Researchers at Oregon State University have discovered a very efficient way of synthesizing Synosutine, which is comparable to Cymbalta in limited in vitro and in vivo assay. This drug could have powerful implications for treatment of depression and neuropathic pain.

 

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Inhibitor(s) of Transporters of Uptake of Monoaminergic Neurotransmitters US Non-provisional United States 13/355,371 8,772,330 1/20/2012 7/8/2014 7/28/2032
Tech ID:
OSU-06-07
Category(s):
Chemistry
Contact:
Jianbo Hu
IP & Licensing Manager
Oregon State University
541-737-2366
Jianbo.Hu@oregonstate.edu
Inventors:
James White
David Chan
David Wong
Rajan Juniku
Jongtae Yang
Keywords:
Pharmaceuticals
Biomedical
© 2017. All Rights Reserved. Powered by Inteum